26.06.2012 • News

Siegfried Appoints René Imwinkelried Head of R&D

The Board of Directors of Siegfried Holding appointed René Imwinkelried, Ph.D., the company's new Head Research & Development and member of the Executive Committee. He is currently Head of Technical Development Small Molecules at Roche in Basel. René Imwinkelried will start in his new function on September 1st, 2012.

He succeeds Wolfgang Wienand, Ph.D., who held this position since August 2010 and will now focus on further developing Strategy and Mergers & Acquisitions in the Executive Committee and on his responsibility for Legal and IP Management. Wolfgang Wienand will continue to execute both functions until René Imwinkelried joins Siegfried.

For personal reasons, Beat In-Albon, Ph.D., has with immediate effect resigned from the Board of Directors of Siegfried Holding.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.